Frontiers in Oncology (Aug 2020)
Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2
- Shuang Dong,
- Shuang Dong,
- Shuang Dong,
- Chenggang Luo,
- Chenggang Luo,
- Chenggang Luo,
- Chenggang Luo,
- Xuebo Hu,
- Jing Zhang,
- Jing Zhang,
- Jing Zhang,
- Qian Cai,
- Qian Cai,
- Qian Cai,
- Yu Qian,
- Yu Qian,
- Yu Qian,
- Fengming Ran,
- Fengming Ran,
- Fengming Ran,
- Wuling Ou,
- Wuling Ou,
- Wuling Ou,
- Wuling Ou,
- Jun Wang,
- Jun Wang,
- Jun Wang,
- Qing Huang,
- Qing Huang,
- Qing Huang,
- Tianhua Ren,
- Guang Han,
- Guang Han,
- Guang Han,
- Feng Zhang,
- Feng Zhang,
- Feng Zhang,
- Wei Wei,
- Wei Wei,
- Wei Wei,
- Wei Wei,
- Xinjun Liang,
- Xinjun Liang,
- Xinjun Liang,
- Huiting Xu,
- Huiting Xu,
- Huiting Xu,
- Sheng Wang,
- Sheng Wang,
- Sheng Wang,
- Lulu Shi,
- Lulu Shi,
- Lulu Shi,
- Lulu Shi,
- Shaozhong Wei,
- Shaozhong Wei,
- Shaozhong Wei,
- Shaozhong Wei,
- Shaozhong Wei,
- Sheng Hu,
- Sheng Hu,
- Sheng Hu,
- Sheng Hu,
- Sheng Hu
Affiliations
- Shuang Dong
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Shuang Dong
- Hubei Provincial Cancer Center, Wuhan, China
- Shuang Dong
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Chenggang Luo
- Hubei Provincial Cancer Center, Wuhan, China
- Chenggang Luo
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Chenggang Luo
- The Cancer Quality Control Center of Hubei Province, Wuhan, China
- Chenggang Luo
- Department of Radiological Intervention, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Xuebo Hu
- Laboratory of Drug Discovery and Molecular Engineering, Department of Medicinal Plants, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan, China
- Jing Zhang
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Jing Zhang
- Hubei Provincial Cancer Center, Wuhan, China
- Jing Zhang
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Qian Cai
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Qian Cai
- Hubei Provincial Cancer Center, Wuhan, China
- Qian Cai
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Yu Qian
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Yu Qian
- Hubei Provincial Cancer Center, Wuhan, China
- Yu Qian
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Fengming Ran
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Fengming Ran
- Hubei Provincial Cancer Center, Wuhan, China
- Fengming Ran
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Wuling Ou
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Wuling Ou
- Hubei Provincial Cancer Center, Wuhan, China
- Wuling Ou
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Wuling Ou
- The Cancer Quality Control Center of Hubei Province, Wuhan, China
- Jun Wang
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Jun Wang
- Hubei Provincial Cancer Center, Wuhan, China
- Jun Wang
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Qing Huang
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Qing Huang
- Hubei Provincial Cancer Center, Wuhan, China
- Qing Huang
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Tianhua Ren
- Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
- Guang Han
- Hubei Provincial Cancer Center, Wuhan, China
- Guang Han
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Guang Han
- Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Feng Zhang
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Feng Zhang
- Department of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Feng Zhang
- 0The Administration of Cancer Clinical Trials and GCP, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Wei Wei
- Hubei Provincial Cancer Center, Wuhan, China
- Wei Wei
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Wei Wei
- The Cancer Quality Control Center of Hubei Province, Wuhan, China
- Wei Wei
- 1Radiotherapy Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Xinjun Liang
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Xinjun Liang
- Hubei Provincial Cancer Center, Wuhan, China
- Xinjun Liang
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Huiting Xu
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Huiting Xu
- Hubei Provincial Cancer Center, Wuhan, China
- Huiting Xu
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Sheng Wang
- Hubei Provincial Cancer Center, Wuhan, China
- Sheng Wang
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Sheng Wang
- 2Department of Thoracic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Lulu Shi
- Hubei Provincial Cancer Center, Wuhan, China
- Lulu Shi
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Lulu Shi
- The Cancer Quality Control Center of Hubei Province, Wuhan, China
- Lulu Shi
- 0The Administration of Cancer Clinical Trials and GCP, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Shaozhong Wei
- Hubei Provincial Cancer Center, Wuhan, China
- Shaozhong Wei
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Shaozhong Wei
- The Cancer Quality Control Center of Hubei Province, Wuhan, China
- Shaozhong Wei
- 3Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Shaozhong Wei
- 3Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Sheng Hu
- Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- Sheng Hu
- Hubei Provincial Cancer Center, Wuhan, China
- Sheng Hu
- The Office of Hubei Provincial Cancer Prevention, Wuhan, China
- Sheng Hu
- The Cancer Quality Control Center of Hubei Province, Wuhan, China
- Sheng Hu
- 3Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- DOI
- https://doi.org/10.3389/fonc.2020.01555
- Journal volume & issue
-
Vol. 10
Abstract
The sudden pandemic of SARS-Cov-2 (also known as novel coronavirus disease 2019, COVID-19) poses a severe threat to hundreds of millions of lives in the world. The complete cure of the virus largely relies on the immune system, which becomes particularly a challenge for the cancer subjects, whose immunity is generally compromised. However, in a constant evolving situation, the clinical data on the prevalence of SARS-Cov-2 for cancer patients is still limited. On top of a wide range of medical references and interim guidelines including CDC, NCI, ASCO, ESMO, NCCN, AACR, ESMO, and the National Health Commission of China, etc., we formed into a guideline based on our experience in our specialized cancer hospital in Wuhan, the originally endemic center of the virus. Furthermore, we formulated an expert consensus which was developed by all contributors from different disciplines after fully discussion based on our understanding and analysis of limited information of COVID-19. The consensus highlighted a multidisciplinary team diagnostic model with assessment of the balance between risks and benefits prior to treatment, individualizing satisfaction of patients’ medical needs, and acceptability in ethics and patients’ socio-economic conditions.
Keywords
